1.30
+0.01(+0.78%)
Currency In USD
| Previous Close | 1.29 |
| Open | 1.28 |
| Day High | 1.33 |
| Day Low | 1.26 |
| 52-Week High | 6.77 |
| 52-Week Low | 1.09 |
| Volume | 3.07M |
| Average Volume | 5.24M |
| Market Cap | 185.66M |
| PE | -4.81 |
| EPS | -0.27 |
| Moving Average 50 Days | 1.54 |
| Moving Average 200 Days | 2 |
| Change | 0.01 |
If you invested $1000 in Humacyte, Inc. (HUMA) since IPO date, it would be worth $134.44 as of December 04, 2025 at a share price of $1.3. Whereas If you bought $1000 worth of Humacyte, Inc. (HUMA) shares 3 years ago, it would be worth $401.23 as of December 04, 2025 at a share price of $1.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results
GlobeNewswire Inc.
Nov 20, 2025 1:00 PM GMT
– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels – – Positive outcomes for dialysis patients sufferin
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)
GlobeNewswire Inc.
Nov 13, 2025 1:00 PM GMT
DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the details of six
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025
GlobeNewswire Inc.
Nov 10, 2025 1:00 PM GMT
– The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – – The significantly longer duration of ATEV use in these high-